| GTO ID | GTC3583 |
| Trial ID | NCT06028347 |
| Disease | Influenza |
| Therapy | mRNA vaccine |
| Treatment | sa-mRNA Vaccine |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase 1, Randomized, Placebo-Controlled, Observer Blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Investigational Self-Amplifying mRNA Influenza Vaccine in Healthy Adults |
| Year | 2023 |
| Country | Australia |
| Company sponsor | Seqirus |
| Other ID(s) | V202_01 |
| Cohort1: sa-mRNA | |||||||
|
|||||||
| Cohort2: Placebo | |||||||
|
|||||||